Video

Dr. Siefker-Radtke on Unmet Needs in Frontline Urothelial Cancer Treatment

Arlene O. Siefker-Radtke, MD, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma treatment.

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma (mUC) treatment.

A majority of patients with mUC are elderly or have associated comorbid conditions that could negatively affect their disease state, Siefker-Radtke explains. Additionally, less than half of patients diagnosed with mUC are eligible for cisplatin-based chemotherapy, the current standard of care (SOC).

The FDA approval of immune checkpoint inhibitors (ICIs) for platinum-ineligible patients has helped improve treatment options in the first-line setting, Siefker-Radtke continues. Development of the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) could also be incredibly promising. This drug has been associated with encouraging overall response rates (ORRs) in the second line, and results from the phase 1B/2 EV-103 trial (NCT03288545) showed that enfortumab vedotin in combination with the ICI pembrolizumab (Keytruda) elicited an ORR in 64.5% of patients with cisplatin-ineligible, locally advanced or metastatic UC.

These data are highly encouraging for clinicians seeking to ameliorate this unmet need through the development of alternative treatment strategies, Siefker-Radtke concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity